All In Biotech

Drug Trial Radar · NCT07618624

BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression

Finotonlimab Combined With Cetuximab and Docetaxel as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Immunotherapy Progression: A Multicenter, Single-Arm, Phase II Clinical Study

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

42

Planned (sponsor's estimate)

Start

Apr 20, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shenzhou Cell Engineering Co., Ltd.
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, single-arm, phase II clinical study evaluating the efficacy and safety of neoadjuvant finotonlimab (anti-PD-1), cetuximab (anti-EGFR), and docetaxel in patients with resectable recurrent head and neck squamous cell carcinoma (HNSCC) who have progressed after prior PD-1(L1) inhibitor plus platinum-based therapy. A total of 42 patients (PD-L1 CPS at least 1) will be enrolled using Simon's two-stage design across 9 centers in China (Stage 1: 25 patients; Stage 2: 17 additional patients with 5% dropout). Enrolled patients will receive 3 cycles of neoadjuvant finotonlimab (200 mg, IV, Q3W), cetuximab (500 mg/m2, IV, Q3W), and docetaxel (75 mg/m2, IV, Q3W), followed by salvage surgery (3-4 weeks later), adjuvant radiotherapy +/- chemotherapy per NCCN/CSCO guidelines, and maintenance finotonlimab 200 mg + cetuximab 500 mg/m2 Q3W for up to 12 cycles or until disease progression or unacceptable toxicity. The primary endpoint is major pathological response (MPR) rate. Historical MPR is 14% with dual immunotherapy neoadjuvant therapy; target MPR is 30% (alpha=0.05, power=0.8, one-sided). Secondary endpoints include ORR, pCR, mOS, mPFS, DoR, 6-month and 12-month PFS rate, and safety (AEs/SAEs per CTCAE v5.0).

Conditions

  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Head and Neck Cancer

Interventions

  • FinotonlimabDrug

    Finotonlimab

  • CetuximabDrug

    Cetuximab

  • DocetaxelDrug

    Docetaxel

  • Salvage SurgeryProcedure

    Surgical resection after neoadjuvant therapy.

  • Adjuvant RadiotherapyRadiation

    Adjuvant radiotherapy: after surgery, the team will assess whether the patient has indications for radiotherapy to determine whether to administer it.

  • Platinum-based ChemotherapyDrug

    Adjuvant chemotherapy determined by team assessment of chemotherapy indications after surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Pathological Response Rate (MPR)Time frame: At time of surgery, approximately 12 weeks after enrollment

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • The First People's Hospital of Foshan

    Foshan, Guangdong, China

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.